Nonalcoholic Fatty Liver Disease and the Risk of Atrial Fibrillation

  • Mahmoud A. Abou Omar Department of Cardiology, Tanta University, Tanta, Egypt
  • Ahmed Alaarag Department of Cardiology, Tanta University, Tanta, Egypt
  • Sherief Abd-Elsalam Department of Tropical Medicine, Tanta University, Tanta, Egypt
  • Mohamed El-Abgeegy Department of Hepatology, Tropical Medicine and Infectious Diseases, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
  • Rehab Ahmed Department of Hepatology, Tropical Medicine and Infectious Diseases, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
  • Ahmed Abdelhaleem Mohamed Department of Hepatology, Tropical Medicine and Infectious Diseases, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
  • Mahmoud Khalil Department of Hepatology, Tropical Medicine and Infectious Diseases, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt
  • Yousry Esam-Eldin Abo-Amer Department of Hepatology, Gastroenterology and Infectious Diseases, Mahala Hepatology Teaching Hospital, Gharbia, Egyp
  • Mahmoud Elkadeem Department of Tropical Medicine, Tanta University, Tanta, Egypt
  • Mohamed Yousef Department of Tropical Medicine, Tanta University, Tanta, Egypt
Keywords: Atrial fi brillation, Nonalcoholic fatty liver disease, Liver disease, Obesity, Cardiac disease, Prevalence

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is now the factor behind the development of liver cirrhosis, liver cell failure, and liver transplantation in many cases. However, its relation to atrial fibrillation (AF) could not be cleared up.

AIM: The purpose of the study was to evaluate prevalence of AF in the setting of NAFLD; the association between them, and to evaluate risk factors of AF in this category of patients.

METHODS: This cross-sectional study was performed on 400 patients between January 2018 and June 2019. These patients were analyzed for the presence of NAFLD and presence of persistent or chronic AF.

RESULTS: There were 138 patients with NAFLD, and 20 patients with persistent or permanent AF. Factors associated with AF were old age, male gender, and high values of aspartate aminotransferase, alanine-aminotransferase, γ-glutamyltranspeptidase, and serum uric acid. The participants with AF had a significantly greater prevalence of NAFLD than those without AF.

CONCLUSION: Incidence and prevalence of atrial fibrillation in NAFLD patients were high. Severity of liver disease was an important predictor of new-onset atrial fibrillation.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Dumcke CW, Moller S. Autonomic dysfunction in cirrhosis and portal hypertension. Scand J Clin Lab Invest. 2008;68(6):437- 47. https://doi.org/10.1080/00365510701813096 PMid:18609092

Rangari M, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. Am J Gastroenterol. 2002;97(3):707-13. https:// doi.org/10.1111/j.1572-0241.2002.05551.x PMid:11922567

Voigt MD, Trey G, Levitt NS, Raine R, Lombard CJ, Robson SC, Gordon G, Kirsch RE. Autonomic neuropathy in extra-hepatic portal vein thrombosis: Evidence for impaired autonomic reflex arc. J Hepatol. 1997;26(3):634-41. https://doi.org/10.1016/ s0168-8278(97)80430-8 PMid:9075672

Patel P, Dokainish H, Tsai P, Lakkis N. Update on the association of inflammation and atrial fibrillation. J CardiovascElectrophysiol. 2010;21(9):1064-70. https://doi. org/10.1111/j.1540-8167.2010.01774.x PMid:20455973

Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: Pathophysiology and therapy. Circ Res. 2014;114(9):1500-15. https://doi. org/10.1161/circresaha.114.303772 PMid:24763467

Lee H, Choi EK, Rhee TM, Lee SR, Lim WH, Kang SH, et al. Cirrhosis is a risk factor for atrial fibrillation: A nationwide, population-based study. Liver Int. 2017;37(11):1660-7. https:// doi.org/10.1111/liv.13459 PMid:28432810.

Mwalitsa JP, Maimone S, Filomia R, Alibrandi A, Saitta C, Caccamo G, et al. Atrial fibrillation in patients with cirrhosis. Liver Int. 2016;36(3):395-400. https://doi.org/10.1111/liv.12928 PMid:26235424

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. https://doi. org/10.1002/hep.28431 PMid:26707365

Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-90. https://doi. org/10.1038/nrgastro.2013.171 PMid:24042449

Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (Published in Chinese on Chinese Journal of Hepatology 2010;18:163-166. J Dig Dis. 2011;12(1):38-44. https://doi.org/10.1111/j.1751-2980.2010.00476.x PMid:21276207

Farrell GC, Wong VW, Chitturi S. NAFLD in Asia as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013;10(5):307-18. https://doi.org/10.1038/nrgastro.2013.34 PMid:23458891

Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al. Non obese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51(5):1593-602. https://doi. org/10.1002/hep.23567 PMid:20222092

Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: A preliminary ultrasonographic survey. Trop Gastroenterol. 2004;25(2):76-9. PMid:15471321

Targher G, Byrne CD. Clinical review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for Type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98(2):483- 95. https://doi.org/10.1210/jc.2012-3093 PMid:23293330

Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11(11):639-54. https:// doi.org/10.1038/nrcardio.2014.118 PMid:25113750

Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study). PLoS One. 2015;10(11):e0142937. https://doi. org/10.1371/journal.pone.0142937 PMid:26571029

Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with Type 2 diabetes. Clin Sci. 2013;125(6):301-9. https://doi.org/10.1042/cs20130036 PMid:23596966

Targher G, Valbusa F, Bonapace S, Rigolon R, Dauriz M, Zoppini G, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with Type 2 diabetes. PLoS One. 2013;8(2):e57183. https://doi. org/10.1371/journal.pone.0057183 PMid:23451184

Markus MR, Meffert PJ, Baumeister SE, Lieb W, Siewert U, Schipf S, et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population. The study of health in Pomerania (SHIP). Atherosclerosis. 2016;245:123-31. https://doi.org/10.1016/j. atherosclerosis.2015.12.023 PMid:26722832

Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among Type 2 diabetic patients. Diabetes. 2005;54(12):3541-6. https://doi.org/10.2337/ diabetes.54.12.3541 PMid:16306373

Zhou Y, Lai C, Peng C, Chen M, Li B, Wang X, et al. Non alcoholic fatty liver disease as a predictor of atrial fibrillation: A systematic review and meta-analysis. Postępy Kardiol Interwencyjnej. 2017;13(3):250-7. https://doi.org/10.5114/aic.2017.70198 PMid:29056998

Ding YH, Ma Y, Qian LY, Xu Q, Wang LH, Huang DS, et al. Linking atrial fibrillation with non-alcoholic fatty liver disease: Potential common therapeutic targets. Oncotarget. 2017;8(36):60673-83. https://doi.org/10.18632/oncotarget.19522 PMid:28948002

Wijarnpreecha K, Boonpheng B, Thongprayoon C, Jaruvongvanich V, Ungprasert P. The association between nonalcoholic fatty liver disease and atrial fibrillation: A metaanalysis. Clin Res Hepatol Gastroenterol. 2017;41(5):525- 32. https://doi.org/10.1016/j.clinre.2017.08.001 PMid:28866089

Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, Magnani JW, et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol. 2013;111(2):219- 24. https://doi.org/10.1016/j.amjcard.2012.09.021 PMid:23127690

Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liverdisease. J Hepatol. 2008;49(4):608-12. https://doi.org/10.1016/j. jhep.2008.06.018 PMid:18682312

Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595-602. https://doi.org/10.1002/hep.23314

Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006;43(5):1145-51. https://doi.org/10.1002/hep.21171 PMid:16628637

Abdelmoemen G, Khodeir SA, Zaki AN, Kassab M, Abou-Saif S, Abd-Elsalam S. Overexpression of hepassocin in diabetic patients with nonalcoholic fatty liver disease may facilitate increased hepatic lipid accumulation. Endocr Metab Immune Disord Drug Targets. 2019;19(2):185-8. https://doi.org/10.2174/ 1871530318666180716100543 PMid:30009716

Wasfy E, Elkassas G, Elnawasany S, Elkasrawy K, Abd- Elsalam S, Soliman S, et al. Predicting esophageal varices in cirrhotic hepatitis C virus patients using noninvasive measurement of insulin resistance variables. Endocr Metab Immune Disord Drug Targets. 2018;18(6):573-80. https://doi.org /10.2174/1871530318666180803120428 PMid:30073932

Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752- 61. https://doi.org/10.1172/jci21625 PMid:15599400

Ndumele CE, Nasir K, Conceic RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31(8):1927-32. https://doi.org/10.1161/ atvbaha.111.228262 PMid:21546603

Harada M, VanWagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 2015;79(3):495-502. https://doi.org/10.1253/circj.cj-15-0138 PMid:25746525

Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60(22):2263-70. https://doi. org/10.1016/j.jacc.2012.04.063 PMid:23194937

Hanafy AS, Seleem WM, El-Kalla F, Basha MA, Abd- Elsalam S, et al. Efficacy of a non-invasive model in predicting the cardiovascular morbidity and histological severity in non-alcoholic fatty liver disease. Diabetes Metab Syndr 2019;13(3):2272-8. https://doi.org/10.1016/j.dsx.2019.05.032 PMid:31235168

Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in Type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52(22):1793-9. https://doi.org/10.1016/j. jacc.2008.07.062 PMid:19022158

Ozveren O, Izgi C, Eroglu E, Simsek MA, Turer A, Kucukdurmaz Z, et al. Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty-liver disease. Ultrason Imaging. 2015;38(3):225-35. https://doi.org/10.1177/0161734615595015 PMid:26157039

Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, Massaro JM, et al. Pericardial fat, intra thoracic fat, and measures of left ventricular structure and function. Circulation. 2009;119(12):1586-91. https://doi.org/10.1161/ circulationaha.108.828970 PMid:19289634

Chen PS, Turker I. Epicardial adipose tissue and neural mechanisms of atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5(4):618-20. https://doi.org/10.1161/circep.112.974956 PMid:22895598

Newton JL, Pairman J, Wilton K, Jones DE, Day C. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res. 2009;19(6):319-26. https://doi.org/10.1007/ s10286-009-0031-4 PMid:19768633

Liu YC, Hung CS, Wu YW, Lee YC, Lin YH, Lin C, et al. Influence of non alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS One. 2013;8(4):e61803. https://doi.org/10.1371/journal.pone.0061803 PMid:23626730

Park HW, Shen MJ, Fishbein MC, Chen LS, Chen PS. Neural mechanisms of atrial fibrillation. Curr Opin Cardiol. 2012;27(1):24-8. PMid:22139702

Trivedi I, Rinella ME. NAFLD and cardiovascular disease: Can the real association be determined? Curr Hepatitis Rep. 2014;13(2):130-41. https://doi.org/10.1007/s11901 -014-0231-9

Published
2020-05-20
How to Cite
1.
Abou Omar MA, Alaarag A, Abd-Elsalam S, El-Abgeegy M, Ahmed R, Mohamed AA, Khalil M, Abo-Amer YE-E, Elkadeem M, Yousef M. Nonalcoholic Fatty Liver Disease and the Risk of Atrial Fibrillation. Open Access Maced J Med Sci [Internet]. 2020May20 [cited 2020Oct.23];8(B):530-5. Available from: https://www.id-press.eu/mjms/article/view/4319
Section
Gastroenterohepatology